Recursion Pharmaceuticals (NASDAQ:RXRX) Director Sells $97,500.00 in Stock

Posted by Geri Gentry on Aug 6th, 2026

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 30,000 shares of the stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $3.25, for a total value of $97,500.00. Following the transaction, the director directly owned 6,188,287 shares of the company’s stock, valued at approximately $20,111,932.75. This trade represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Blake Borgeson also recently made the following trade(s):

On Tuesday, July 7th, Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.96, for a total value of $158,400.00.
On Tuesday, June 2nd, Blake Borgeson sold 30,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.68, for a total value of $110,400.00.

Recursion Pharmaceuticals Price Performance

RXRX stock traded up $0.01 on Thursday, reaching $3.18. 14,782,481 shares of the company’s stock were exchanged, compared to its average volume of 18,481,574. The stock has a fifty day moving average of $3.33 and a 200-day moving average of $3.47. The firm has a market cap of $1.69 billion, a PE ratio of -2.65 and a beta of 1.03. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a twelve month low of $2.77 and a twelve month high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The business had revenue of $7.67 million during the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. During the same period last year, the business posted ($0.41) EPS. As a group, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -0.9 EPS for the current fiscal year.

Key Headlines Impacting Recursion Pharmaceuticals

Here are the key news stories impacting Recursion Pharmaceuticals this week:

Positive Sentiment: Genentech collaboration advanced: Genentech opted to move the partnership’s first neuroscience target into a joint early-discovery program. This is an early validation of Recursion’s AI-enabled drug-discovery platform and could support future collaboration economics. Recursion Reports Second Quarter Financial Results
Positive Sentiment: Pipeline milestones continue: REC-7735 received IND clearance, with its Phase 1/2 ZINNIA study expected to begin in the second half of 2026. Recursion also expects additional Phase 2 data for REC-4881 in November, while other clinical programs remain on schedule. Recursion Reports Second Quarter Financial Results
Positive Sentiment: Spending outlook improved: Recursion outlined approximately $375 million in 2026 cash operating expenses, indicating continued cost discipline as it advances its clinical pipeline. Recursion Outlines 2026 Cash Operating Expense Guidance
Neutral Sentiment: Loss narrowed year over year: Second-quarter loss improved to $0.25 per share from $0.41 a year earlier, but Recursion remains deeply unprofitable. Investors are likely to focus on whether pipeline progress can eventually translate into recurring revenue.
Negative Sentiment: Quarterly results missed expectations: Recursion reported a loss of $0.25 per share versus the $0.24 consensus estimate, while revenue fell to $7.67 million from $19.22 million a year earlier and missed estimates of approximately $10.97 million. The decline was primarily linked to lower collaboration revenue, weighing on the near-term earnings outlook. RXRX Q2 Earnings Miss Estimates
Negative Sentiment: Valuation remains a concern: Despite the company’s long-term platform potential, analysts and market commentary continue to view RXRX as expensive relative to its current revenue base, ongoing losses and sharply negative margins. Recursion Pharmaceuticals Stock Still Looks Expensive

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its holdings in shares of Recursion Pharmaceuticals by 18.6% in the fourth quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock valued at $192,998,000 after purchasing an additional 7,407,606 shares in the last quarter. State Street Corp grew its position in shares of Recursion Pharmaceuticals by 38.7% in the fourth quarter. State Street Corp now owns 25,333,888 shares of the company’s stock valued at $103,616,000 after purchasing an additional 7,064,963 shares during the last quarter. Norges Bank acquired a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at approximately $23,473,000. ARK Investment Management LLC increased its stake in shares of Recursion Pharmaceuticals by 11.2% during the 4th quarter. ARK Investment Management LLC now owns 37,316,856 shares of the company’s stock worth $152,626,000 after purchasing an additional 3,771,357 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $7,370,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on RXRX. JPMorgan Chase & Co. reduced their price objective on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Morgan Stanley upped their target price on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research report on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Two investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $8.10.

Check Out Our Latest Stock Analysis on Recursion Pharmaceuticals

Recursion Pharmaceuticals Company Profile

(Get Free Report)

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.